Quality Regulations: Unterschied zwischen den Versionen
(Die Seite wurde neu angelegt: „== Scope == == Regulations for Cultivation & Collection == WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants, 2003 (Li…“) |
|||
| (3 dazwischenliegende Versionen von 2 Benutzern werden nicht angezeigt) | |||
| Zeile 4: | Zeile 4: | ||
WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants, 2003 (Link to WHO) | WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants, 2003 (Link to WHO) | ||
| + | |||
| + | [https://apps.who.int/iris/bitstream/handle/10665/42783/9241546271.pdf;sequence=1 WHO GACP Guideline] | ||
== Regulations for Processing, Packaging and Storage == | == Regulations for Processing, Packaging and Storage == | ||
| Zeile 9: | Zeile 11: | ||
=== Requirements Health Canada === | === Requirements Health Canada === | ||
Health Canada's Cannabis Regulations SOR/2018-144 requires surveillance of the premises in section 64-66. | Health Canada's Cannabis Regulations SOR/2018-144 requires surveillance of the premises in section 64-66. | ||
| + | |||
| + | [https://laws-lois.justice.gc.ca/eng/regulations/SOR-2018-144/ HC Cannabis Regulations] | ||
| − | GAP Canada Version (current Version | + | GAP Canada Version (current Version 9.0 – April 1, 2021) |
A revision is usually done in February each year. | A revision is usually done in February each year. | ||
| + | |||
| + | [https://www.canadagap.ca/2021/03/canadagap-program-changes-for-2021-and-release-of-version-9-0-of-the-program-management-manual/ GAP Canada V 9.0] | ||
| − | Health Canada; Good Manufacturing Practices (GUI-0001); | + | Health Canada; Good Manufacturing Practices (GUI-0001); July 1, 2020 |
| + | |||
| + | [https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/guidance-documents/gmp-guidelines-0001/document.html HC GMP 2020] | ||
=== European Union === | === European Union === | ||
Reflection paper on microbiological aspects of herbal medicinal products and traditional herbal medicinal products | Reflection paper on microbiological aspects of herbal medicinal products and traditional herbal medicinal products | ||
| − | https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-microbiological-aspects-herbal-medicinal-products-traditional-herbal-medicinal_en.pdf | + | |
| + | [https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-microbiological-aspects-herbal-medicinal-products-traditional-herbal-medicinal_en.pdf EMA Reflection paper] | ||
== Application requirements for cannabis cultivation, processing and medical sales licences == | == Application requirements for cannabis cultivation, processing and medical sales licences == | ||
| Zeile 23: | Zeile 32: | ||
=== Requirements Health Canada === | === Requirements Health Canada === | ||
Application requirements for cannabis cultivation, processing and medical sales licences | Application requirements for cannabis cultivation, processing and medical sales licences | ||
| + | |||
| + | == United Kingdom (UK) == | ||
| + | MHRA Guidance on manufacturing, importing, distributing and supply specially manufactured or ordered products, including cannabis-based products for medicinal use in humans (CBPMs), known as 'specials', March 2020 | ||
| + | |||
| + | [https://www.gov.uk/government/publications/supply-unlicensed-medicinal-products-specials MHRA Guidance] (website) | ||
| + | |||
| + | [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/869284/Cannabis_Guidance__unlicensed_CBPMs__updated_2020.pdf The supply of unlicensed cannabis-based products for medicinal use in humans], 2020 (document) | ||
| + | |||
| + | [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/373505/The_supply_of_unlicensed_medicinal_products__specials_.pdf The supply of unlicensed medicinal products 'specials", MHRA Guidance Note 14], 2014 (document) | ||
Aktuelle Version vom 18. Oktober 2021, 14:07 Uhr
Inhaltsverzeichnis
Scope[Bearbeiten]
Regulations for Cultivation & Collection[Bearbeiten]
WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants, 2003 (Link to WHO)
Regulations for Processing, Packaging and Storage[Bearbeiten]
Requirements Health Canada[Bearbeiten]
Health Canada's Cannabis Regulations SOR/2018-144 requires surveillance of the premises in section 64-66.
GAP Canada Version (current Version 9.0 – April 1, 2021) A revision is usually done in February each year.
Health Canada; Good Manufacturing Practices (GUI-0001); July 1, 2020
European Union[Bearbeiten]
Reflection paper on microbiological aspects of herbal medicinal products and traditional herbal medicinal products
Application requirements for cannabis cultivation, processing and medical sales licences[Bearbeiten]
Requirements Health Canada[Bearbeiten]
Application requirements for cannabis cultivation, processing and medical sales licences
United Kingdom (UK)[Bearbeiten]
MHRA Guidance on manufacturing, importing, distributing and supply specially manufactured or ordered products, including cannabis-based products for medicinal use in humans (CBPMs), known as 'specials', March 2020
MHRA Guidance (website)
The supply of unlicensed cannabis-based products for medicinal use in humans, 2020 (document)
The supply of unlicensed medicinal products 'specials", MHRA Guidance Note 14, 2014 (document)